Interleukin‐33 as an early predictor of cetuximab treatment efficacy in patients with colorectal cancer
Abstract Background Cetuximab is used for colorectal cancer (CRC) treatment. However, the early biomarker of treatment efficacy of cetuximab has not been identified. Methods After 1 year of cetuximab treatment, patients were divided into an effective group and an ineffective group. The interleukin‐3...
Guardado en:
| Autores principales: | , , , , , , , , , , |
|---|---|
| Formato: | article |
| Lenguaje: | EN |
| Publicado: |
Wiley
2021
|
| Materias: | |
| Acceso en línea: | https://doaj.org/article/a90dc28a276847e28e408e853d44edcc |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|